Predictive factors of the pharmacological action of tolvaptan in patients with liver cirrhosis: a post hoc analysis

BACKGROUND: Tolvaptan has been approved in Japan for the treatment of hepatic edema. An important consideration in providing a clinical benefit to patients with liver cirrhosis is the improvement of ascites-related clinical symptoms. In the present post hoc analysis, we aimed to identify factors tha...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakaida, Isao, Terai, Shuji, Nakajima, Koji, Shibasaki, Yoshiyuki, Tachikawa, Sayaka, Tsubouchi, Hidetsugu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2016
Materias:
Original Article—Liver, Pancreas, and Biliary Tract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5281662/
https://www.ncbi.nlm.nih.gov/pubmed/27379386
http://dx.doi.org/10.1007/s00535-016-1233-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5281662/
https://www.ncbi.nlm.nih.gov/pubmed/27379386
http://dx.doi.org/10.1007/s00535-016-1233-x

Ejemplares similares